CenterBook Partners LP Purchases 117,288 Shares of GH Research PLC $GHRS

CenterBook Partners LP increased its position in shares of GH Research PLC (NASDAQ:GHRS) by 70.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 283,441 shares of the company’s stock after buying an additional 117,288 shares during the quarter. CenterBook Partners LP owned 0.54% of GH Research worth $3,600,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. HighVista Strategies LLC grew its stake in GH Research by 363.0% in the third quarter. HighVista Strategies LLC now owns 241,894 shares of the company’s stock valued at $3,459,000 after purchasing an additional 189,647 shares in the last quarter. BIT Capital GmbH bought a new position in GH Research in the fourth quarter valued at approximately $635,000. AdvisorShares Investments LLC grew its stake in GH Research by 24.3% in the fourth quarter. AdvisorShares Investments LLC now owns 67,112 shares of the company’s stock valued at $852,000 after purchasing an additional 13,121 shares in the last quarter. Jefferies Financial Group Inc. grew its stake in GH Research by 0.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock valued at $9,046,000 after purchasing an additional 2,988 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in GH Research in the fourth quarter valued at approximately $128,000. 56.90% of the stock is currently owned by institutional investors.

GH Research Trading Down 6.1%

Shares of NASDAQ GHRS opened at $20.12 on Tuesday. GH Research PLC has a 12 month low of $11.32 and a 12 month high of $25.94. The stock has a 50 day moving average of $19.66 and a 200-day moving average of $16.54. The company has a market capitalization of $1.38 billion, a P/E ratio of -21.87 and a beta of 1.31.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Analysts predict that GH Research PLC will post -1.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GHRS has been the subject of a number of analyst reports. Cantor Fitzgerald raised their price target on GH Research from $25.00 to $35.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Citigroup restated an “outperform” rating on shares of GH Research in a research note on Friday, May 15th. HC Wainwright decreased their price target on GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Citizens Jmp decreased their price target on GH Research from $42.00 to $39.00 and set a “market outperform” rating for the company in a research note on Friday, May 15th. Finally, Guggenheim set a $34.00 price target on GH Research and gave the company a “buy” rating in a research note on Tuesday, March 10th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, GH Research currently has an average rating of “Moderate Buy” and an average price target of $40.38.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.